V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20203961 | 20134779 | 1.69 | 62.8 | Neo-adjuvant (N) | 2019-05-07 | 2019-05-07 | Trabectedin | 2 | null | IBRUTINIB | 100699246 |
| 20204002 | 20134780 | 1.73 | 84.5 | Palliative (P) | 2018-11-09 | 2018-11-09 | Cisplatin + Docetaxel +Fluorouracil | N | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101176113 |
| 20204109 | 20134783 | 1.58 | 72.6 | Curative (C) | 2019-01-10 | 2019-05-04 | Bevacizumab + Irinotecan + MdG | N | N | IBRUTINIB | 100726984 |
| 20204196 | 20134784 | 1.8 | 96 | 03 | 2017-10-05 | 2017-10-05 | Gemcitabine+Paclitaxel (Neo-tAnGo) | 02 | N | LETROZOLE + PALBOCICLIB | 101749305 |
| 20204380 | 20134785 | null | null | Palliative (P) | 2019-03-18 | 2019-04-25 | ESHAP | N | N | BALLAD TRIAL | 100099922 |
| 20204408 | 20134786 | 1.72 | 120.2 | Curative (C) | 2018-01-07 | 2018-01-07 | Cape+Cetuximab+Oxalip (2 wk) Load | 02 | N | BEVACIZUMAB + CAPECITABINE + OXALIPLATIN | 101403143 |
| 20204423 | 20134787 | 1.75 | 70 | null | 2019-10-05 | 2019-11-17 | PHITT D Carboplatin/Doxorubicin | 02 | null | ECF | 100383333 |
| 20204466 | 20134789 | 1.83 | 98 | 03 | 2017-03-06 | 2017-04-22 | EW EuroEwing 2012 Arm A VAC | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 101045666 |
| 20204510 | 20134790 | 1.52 | 76.5 | 03 | 2020-05-09 | 2020-05-09 | FCR Oral - Cycle 2 onwards | 02 | N | BEVACIZUMAB + CAPECITABINE + OXALIPLATIN | 101478155 |
| 20204719 | 20134792 | 1.49 | 161.9 | Palliative (P) | 2018-09-16 | 2018-09-27 | Ixazomib + Lenalidomide | 02 | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100246611 |
| 20204742 | 20134793 | 1.79 | 61.2 | Curative (C) | 2018-03-29 | 2018-04-22 | Docetaxel + nintedanib | 02 | N | CYCLOPHOSPHAMIDE + POMALIDOMIDE | 100327205 |
| 20204845 | 20134794 | 1.47 | 69.4 | Curative (C) | 2019-05-11 | 2019-10-22 | CAV | 02 | N | POLEM TRIAL | 100673378 |
| 20204955 | 20134795 | 1.72 | 72.6 | Adjuvant (A) | 2021-03-02 | 2021-03-30 | null | 02 | N | CISPLATIN + VINORELBINE | 100856300 |
| 20205115 | 20134796 | 1.69 | 47.1 | null | null | 2018-06-10 | CYCLOPHOSPHAMIDE | null | N | BORTEZOMIB + CYCLOPHOSPHAMIDE | 101497520 |
| 20205252 | 20134797 | 1.38 | 85 | null | 2021-02-04 | 2021-02-04 | Hydroxycarbamide | 01 | N | RIPRETINIB | 101853630 |
| 20205393 | 20134798 | 1.65 | 48.4 | Palliative (P) | 2019-08-06 | 2019-10-31 | Palbociclib | 02 | null | FLUOROURACIL + RT | 100502456 |
| 20205425 | 20134799 | 1.8 | 61.5 | Palliative (P) | null | 2016-02-08 | ECF | null | N | TRASTUZUMAB + VINORELBINE | 101035569 |
| 20205510 | 20134800 | 1.57 | 71.2 | Curative (C) | 2018-05-12 | 2018-05-16 | CISPLATIN + FLUOROURACIL + Trastuzumab | 02 | N | GEMCITABINE + OXALIPLATIN | 101192417 |
| 20205619 | 20134801 | 1.8 | 59.8 | Palliative (P) | 2018-10-27 | 2018-10-28 | PHITT Trial | 02 | N | ECARBOX | 101747743 |
| 20205674 | 20134802 | 1.75 | 84.1 | Palliative (P) | 2017-07-22 | 2018-10-09 | PHITT D SIOPEL-4 (A1, A2, A3) | null | Y | CISPLATIN + VINORELBINE | 101791858 |
| 20205748 | 20134803 | 1.82 | null | Neo-adjuvant (N) | 2017-07-27 | 2017-08-22 | Rituximab | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100908183 |
| 20205829 | 20134805 | 1.65 | 58.7 | Palliative (P) | 2017-09-20 | 2018-08-01 | Gemcitabine + Oxaliplatin | 02 | N | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE | 101085882 |
| 20205943 | 20134807 | 1.6 | 60 | Curative (C) | 2020-03-28 | 2020-08-16 | CAPECITABINE + LOMUSTINE | 02 | null | BORTEZOMIB + PANOBINOSTAT | 100289612 |
| 20205960 | 20134808 | 1.65 | null | null | 2018-10-12 | 2018-10-19 | EC | 02 | N | FCIST | 100832654 |
| 20206048 | 20134809 | 1.72 | 70 | Palliative (P) | 2019-10-02 | 2019-10-19 | NEO-AEGIS TRIAL | 02 | N | OXALIPLATIN + MDG + PANITUMUMAB | 101257517 |
| 20206119 | 20134810 | 1.53 | 10.8 | Curative (C) | 2017-12-08 | 2017-12-08 | Temozolomide 150mg/m2 | 02 | null | CAPECITABINE + IRINOTECAN + PANITUMUMAB | 100637538 |
| 20206191 | 20134811 | 1.89 | 51 | Palliative (P) | null | 2019-06-17 | CAV | N | null | IPILIMUMAB + NIVOLUMAB | 100692362 |
| 20206326 | 20134812 | 1.6 | 62.6 | Palliative (P) | 2020-05-06 | 2020-05-07 | CARBOPLATIN + GEMCITABINE | 02 | N | TOPOTECAN | 101105685 |
| 20206363 | 20134813 | 1.55 | 55.2 | null | 2018-06-30 | 2018-07-21 | Carboplatin + Docetaxel | 02 | N | CAPECITABINE + CISPLATIN + STREPTOZOCIN | 100223109 |
| 20206378 | 20134814 | 1.65 | 65.2 | Curative (C) | 2020-09-22 | 2020-09-23 | ECF | 2 | null | CYCLOPHOSPHAMIDE + OBINUTUZUMAB + VINCRISTINE | 100834138 |
| 20206443 | 20134815 | 1.75 | 0 | Adjuvant (A) | 2018-10-30 | 2018-11-01 | CAPE + OXALIPLATIN + TRASTUZUMAB | 02 | N | TEMOZOLOMIDE + RT | 101450822 |
| 20206480 | 20134816 | 0 | 71 | Curative (C) | 2018-03-29 | 2018-04-03 | BORTEZOMIB + THALIDOMIDE | N | N | PEMETREXED | 100364677 |
| 20206498 | 20134817 | 1.57 | 60 | null | 2018-08-05 | 2018-08-16 | Bevacizumab + FLUOROURACIL + IRINOTECAN | 02 | null | LIPOSOMAL DOXORUBICIN | 101349727 |
| 20206507 | 20134818 | 1.57 | 61.8 | Palliative (P) | 2019-11-12 | 2019-12-20 | Hydroxycarbamide | 02 | null | COSMIC TRIAL | 101620051 |
| 20206530 | 20134819 | 1.89 | 68.6 | Curative (C) | 2019-02-27 | 2019-03-21 | Capecitabine + Streptozocin | 01 | N | BENDAMUSTINE + THALIDOMIDE | 101395576 |
| 20206546 | 20134820 | 1.6 | 60 | Neo-adjuvant (N) | 2017-06-01 | 2017-06-01 | OXALIPLATIN + MDG + PANITUMUMAB | 02 | N | SCOPE2 TRIAL | 100757014 |
| 20206644 | 20134821 | 1.51 | 40.6 | Palliative (P) | 2019-08-14 | 2019-08-14 | null | N | N | MPV | 101417379 |
| 20206746 | 20134822 | 1.56 | 78.2 | Palliative (P) | 2017-12-20 | 2018-12-18 | BORTEZOMIB + THALIDOMIDE | 02 | N | PALBOCICLIB | 101251309 |
| 20206813 | 20134823 | 1.77 | 75 | Palliative (P) | 2018-08-24 | 2018-08-26 | AML17 TRIAL | 02 | null | CISPLATIN + IFOSFAMIDE + MITOMYCIN | 101023740 |
| 20206848 | 20134824 | 1.8 | 95 | Curative (C) | 2018-12-26 | 2019-01-09 | THALIDOMIDE | 02 | null | BORTEZOMIB + RITUXIMAB | 100260014 |
| 20206885 | 20134825 | 1.8 | 88.1 | Palliative (P) | 2017-09-20 | 2017-11-09 | Bevacizumab + Irinotecan + MdG | N | N | CISPLATIN + FLUOROURACIL + RT | 100930268 |
| 20206894 | 20134827 | 1.69 | 74.1 | null | 2018-11-20 | 2018-12-17 | Gemcitabine + RT pancreas | 2 | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 100095617 |
| 20206966 | 20134828 | 1.58 | 81.6 | null | 2019-08-17 | 2019-08-31 | CARBO + FLUOROURACIL | 02 | N | GEMCARBO | 100343657 |
| 20207149 | 20134829 | 1.53 | 67.5 | null | 2018-08-26 | 2019-01-26 | CAPECITABINE + MITOMYCIN + RT | 02 | null | ARISTOTLE TRIAL | 100672045 |
| 20207194 | 20134830 | 1.73 | null | null | 2017-04-15 | 2019-02-10 | Mini BEAM | null | Y | CARBOPLATIN + VINORELBINE | 100428520 |
| 20207338 | 20134831 | 1.82 | 76.7 | Palliative (P) | 2018-01-14 | 2018-02-01 | Bortezomib + Daratumumab | 02 | null | CISPLATIN + FLUOROURACIL + RT | 100323762 |
| 20207341 | 20134832 | 1.75 | 113.5 | Curative (C) | 2017-08-08 | 2017-08-11 | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + Pertuzumab + Trastuzumab | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100844603 |
| 20207351 | 20134833 | 1.57 | 67.2 | null | 2019-05-18 | 2019-05-22 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 2 | N | CARBOPLATIN + VINORELBINE | 101667709 |
| 20207380 | 20134834 | 1.5 | null | Palliative (P) | null | 2021-12-24 | IVA | N | N | CAPECITABINE + STREPTOZOCIN | 101626298 |
| 20207427 | 20134835 | 1.49 | null | 03 | 2020-05-27 | 2020-05-27 | Hepatoblastoma HR Carbo/Dox | 02 | null | CISPLATIN + FU + TRASTUZUMAB | 100064402 |